Skip to content
Search

Latest Stories

Valneva’s Covid-19 vaccine will compete with AstraZeneca and J&J, says GlobalData

The newly launched Covid-19 vaccine by the French pharmaceutical company Valneva will compete with AstraZeneca and Johnson & Johnson (J&J) in the European market, says London-headquartered data analytics and consulting firm, GlobalData.

The new entrant has shown superior neutralising antibody levels and an equal seroconversion rate and protection against Sars-CoV-2, compared to AstraZeneca’s Vaxzevria.


Sharing his view, Philipp Rosenbaum, PhD, senior pharma analyst at GlobalData, said: “Valneva’s promising initial Phase III data, with at least equal protection levels and a superior tolerability profile compared to AstraZeneca’s vaccine”, will make it a strong competitor in the European market for Covid-19 vaccines.

“If Valneva’s safety data holds up, the low risk of thromboses events of AstraZeneca’s and Johnson & Johnson (J&J)’s adenovirus vector-based vaccines may become another important factor in deciding which vaccine to use.

He, however, highlighted that the French company might not be able to match the manufacturing capacity of AstraZeneca and J&J and their partners.

AstraZeneca has a great early-to-market advantage. Besides, its manufacturing collaboration with the Serum Institute of India will enable supply of up to three billion Covid-19 vaccine doses in 2021.

He added that Valneva will have to look for a strong partner and buyers, and evaluate if it can match Vaxzevira’s low price.

He further said the latest data could be a bad news for the adenovirus vector-based vaccine technology.

The French maker uses an inactivated vaccine technology that can be ramped up quickly.

Rosenbaum explains: “The technology involves the virus being grown in cell-culture and then inactivated and additionally uses an adjuvant to enhance the immune response.”

Another advantage of this technology is that it includes all vital proteins unlike in adenovirus vector-based and mRNA vaccines, allowing the human body to develop antibodies to different parts of the virus and enhancing the immune response.

Meanwhile, the duration of protection against Covid-19 will be an interesting data point to observe.

According to the long-term data from Pfizer/BioNTech and Moderna, protection against the infection wanes after six months, making booster jabs necessary for high-risk groups.

In case inactivated vaccine protection lasts longer, the key question will be to decide “whether a higher protection but more frequent boosters are preferable over lower but longer protection.”

Currently, all vaccines show great effectiveness in protection against severe disease and hospitalisation, he added.

More vaccines are expected to be introduced in the market with Novavax close to launch its recombinant nanoparticle vaccine, and Sanofi and GlaxoSmithKline’s recombinant protein vaccine on track to launch next year.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less